Insights from analysts' 12-month price targets are revealed, presenting an average target of $54.15, a high estimate of ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

The drugmaker has been counting on newer launches such as genetic disorder drug Skyclarys as demand falls for its once ...

Liver damage related to Zolgensma gene therapy usually resolves within a few months of treatment, a study found.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March ...

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

Nusinersen is a spinal muscular atrophy drug. Biogen registered the drug under the ... According to the plaintiffs, Generium violated one of the patents for Spinraza held by the American side. SMA is ...

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Eyecyte-RPE trial involved 9 patients with geographic atrophy, using 3 ascending dose levels of hiPSC-derived RPE cells. No serious adverse events were reported, and patients showed an average vision ...